Innovative
Therapeutics for
Better Health

Because Life
Shouldn't Have to
Wait for Migraines

Our Lead Product Candidate

STS101

Dihydroergotamine (DHE) Nasal Powder

Learn More

Clinical Trials

SUMMIT™ Trial

Enrollment Complete

Learn More

Clinical Trials

ASCEND™ Trial

Ongoing

Learn More

Press Releases

Feb 02, 2023

Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference

Read More

Dec 20, 2022

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

Read More